All News

The US pharma market grew just 3.8 percent last year, according to IMS Health. The big loser: lipid regulators. The winners: Biologic response modulators and monoclonal antibodies.

Pharma is still having a hard time earning the confidence of the key opinion elite, as only 56 percent claim they trust the industry.

A Kaiser Foundation study finds that although most Americans look favorably upon pharmaceuticals, they generally think drugs are too expensive and that most of the cost is blown on advertising.

i1-501583-1408667680515.jpg

Pharma companies must quit wasting money and get strategic when mapping out their clinical study strategies

IAG Research released its top-10 list of most-recalled new pharma ads of 2007. Many familiar faces top the list, including the Nasonex bee, Abe Lincoln, and Dr. Jarvik, but how many of those faces will still be there next year?

Avenue A|Razorfish's new digital-outlook report indicates that pharma is still floundering online. Though some pharma companies are taking steps to make their online presence known, others are still crawling.

Jarvik Ads Get KO'd

Under pressure from Congress and public scrutiny, Pfizer voluntarily pulled its controversial television campaign for Lipitor featuring Dr. Jarvik.

Jarvik Ads Draw Fire

Pfizer's consumer ads for Lipitor are causing a stir on the blogs and in Congress. Did the company cross the line by using a famous (but unlicensed) doctor to market a drug, or is this a case of a mistaken identity?

More and more consumers are surfing the Web for information about prescription drugs, but many bypass brand.com sites, a new report says.

Lilly is in the midst of settlement discussions with federal prosecutors over the pharma company?s off-label marketing of the antipsychotic medication Zyprexa. If settled, Lilly could be shelling out more than $1 billion in fines.

Merck is under investigation for allegedly pushing physicians to prescribe Vioxx for unapproved use. Federal investigators are scrutinizing Merck?s marketing and sales practices in search of shady business tactics.

After watching similar legislation barring data mining for Rx info get shut down in Maine and New Hampshire, Vermont changes tactics and amends its law.

Vytorin Scripts Plummet

In the wake of the ENHANCE study, new prescriptions of the cholesterol-lowering drug Vytorin are dropping drastically, but calls to sales reps by physicians are on the rise.

In a surprising but not completely unexpected move, FDA announced last week that its Prescription Drug User Fee Act was dead on arrival. Feds cite lack of funding as main reason.

Managed care pharmacy executives list their favorite pharmaceutical companies based on promotional activities and the ability to meet managed care needs. Novartis reigns for 11th straight quarter.

New study finds that risks and side effects don't get their fair share of time in television advertising. The authors cry out for more educational information in DTC ads--but is it necessary if the ads aren't breaking the law?